Alizyme plc
UK authorities grant approval for trial of ulcerative colitis therapy
Published in Healthcare Mergers, Acquisitions and Ventures Week, April 16th, 2005
The trial will be a randomized, double-blind, active comparator controlled, parallel-group study and will seek to demonstrate similar efficacy of Colal-Pred to conventional oral prednisolone, but with a substantially improved side effect profile.
The trial will involve up to 670 patients who have moderate to severe ulcerative colitis. Patients will undergo 8 weeks of treatment and a 4-week follow-up period. In addition to the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- AMS Health Sciences, Inc.
Nutritional supplements company reports 1.6% decrease in 2004 net sales - Abbott
Pharmaceutical firm announces increase in dividend, new collaboration - Accelr8 Technology Corp.
Medical instrumentation maker reports loss of $0.03 per share - Accelrys, Inc.
Analyst initiates coverage of nanotechnology firm with a buy rating - Advanced Medical Optics, Inc.
Ophthalmic surgical device firm establishes stock trading program - Akers Biosciences, Inc.
Diagnostics company completes $2.5M financing - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
